Exagen Inc. (XGN) fundamentals score
Exagen is a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Services-Medical Laboratories · Healthcare · Listed on NASDAQ
Overall: 5.1 out of 10, Mixed fundamentals
- Growth: 5.3/10
- Profitability: 3.9/10
- Financial health: 4.5/10
- Earnings quality: 7.7/10
- Valuation: 4.8/10
Scores are calculated from Exagen Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10